Solanezumab Terminated Phase 1 Trials for Alzheimer's Disease (AD) / Mild Cognitive Impairment (MCI) / Healthy Volunteers Treatment

IndicationsStatusPurposePhase
TerminatedTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT02614131A Study of LY2599666 in Healthy Participants and Participants With Mild Cognitive Impairment or Alzheimer's Disease (AD)